Lentitek Ltd and Annogen BV have announced a new collaboration aimed at improving the quality and safety of lentivirus-based CAR-T therapies. The partnership was jointly unveiled today at the CGTI Leadership Summit.
The collaboration focuses on overcoming a key challenge in CAR-T therapy development — eliminating undesired transgene expression during viral vector manufacturing and ensuring that CAR expression is restricted to T-cells in vivo.
Annogen has developed a suite of novel, validated promoters that drive strong expression specifically in conventional T-cells, while remaining inactive in more than 20 other cell types, including HEK293T producer cells commonly used in lentiviral vector manufacturing. This targeted precision is vital to maintaining both efficacy and biosafety, as unintended transgene expression during production or in non-target cells can compromise therapeutic performance.
Lentitek contributes its proprietary lentiviral vector manufacturing technology, which prevents incorrect splicing and minimizes unwanted payload expression. By combining these complementary innovations, Lentitek and Annogen aim to set a new standard for next-generation in vivo CAR-T therapies, delivering safer and more effective treatments for patients.
About Lentitek Ltd
Based in Edinburgh, Lentitek has developed a unique manufacturing technology that enhances lentiviral vector quality, purity, and yield by minimising genome splicing and reducing unwanted payload expression.
About Annogen BV
Headquartered in Amsterdam, Annogen is a leading partner for advanced therapy developers, offering off-the-shelf promoters and custom promoter designs validated through extensive in vitro and in vivo screening.